Abstract
Simple SummaryEarly prediction of aggressive cancer using biomarkers is thought to be important for future improvements in the personalized treatment of renal cell carcinoma (RCC). Epigenetic alterations, such as DNA methylation, are promising candidates because they are frequently associated with distant metastasis of tumors and combinations of them offer greater informativity. Here, we describe the indication of the metastatic disease state of renal cell tumors by the methylation of three new candidate genes, INA, NHLH2, and THBS4. The inclusion of the methylation status of these genes could improve the early detection of metastatic tendency in renal tumors and help identify patients who will benefit from adjuvant treatments.The detection of DNA methylation in primary tumor tissues could be relevant for early stratification of aggressive renal cell carcinomas (RCCs) as a basis for future personalized adjuvant therapy. Methylated TCGA KIRC based candidate CpG loci in INA, NHLH2, and THBS4 that are possibly associated with RCC metastasis were evaluated by pyrosequencing in 154 paired normal adjacent and primary tumor tissues, as well as in 202 metastatic tissues. Statistical analysis was carried out by bivariate logistic regression for group comparisons, log rank survival analysis, and unsupervised and supervised analysis for the classification of tumors. Increased methylation of INA, NHLH2, and THBS4 loci were significantly associated with distant metastasis in primary tumors (p < 0.05), tissue-specific hypermethylation in metastatic (p = 7.88 × 10−8, 5.57 × 10−10, 2.06 × 10−7) and tumor tissues (p = 3.72 × 10−24, 3.17 × 10−13, 1.58 × 10−19), and shortened progression free survival in patients (p = 0.03). Combined use of CpG site-specific methylation permits the discrimination of tissues with metastatic disease and reveals a significant contribution of CpG sites in all genes to the statistical classification model. Thus, metastasis in RCC is significantly associated with methylation alterations in INA, NHLH2, and THBS4 loci, providing independent information for the potential early detection of aggressive renal cancers as a rationale for stratifying patients to adjuvant therapies.
Highlights
Renal cell carcinoma (RCC) is the most common kidney neoplasia and is observed in 5% and 3% of all cancer diagnoses in men and women, respectively [1]
Kidney RCC (KIRC) methylation data for 282 tumor tissues were subjected to univariate logistic regression analysis comparing the subsets of 230 M0 and 52 M+ tumors
Statistical evaluation identified CpG sites cg00824018, cg00065905, and cg00795341, which were annotated to intermediate filament protein alpha (INA), nescient helix– loop–helix 2 (NHLH2), and TBHS4, respectively, as being among the top 20 ranked candidates
Summary
Renal cell carcinoma (RCC) is the most common kidney neoplasia and is observed in 5% and 3% of all cancer diagnoses in men and women, respectively [1]. Taking into account that even patients with a clinicopathologically defined localized disease may develop aggressive disease, the need for biomarkers able to guide subsequent clinical decisions based on personalized adjuvant treatment strategies, appears to be evident [6,9]. This is further underlined by recent therapeutic advances demonstrating that subsets of localized RCC with a higher recurrence risk (tumor stage T ≥ 2, differentiation ≥ G3) likely benefit from adjuvant therapy with pembrolizumab, a PD-1 checkpoint inhibitor [10]. Considering that approximately one-third of these patients present with grade 3 and higher adverse events, individualized biomarker-based prediction of response or non-response could reduce non-beneficial treatments [10,11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.